Floatz logo

Abt-263

Chronic Lymphoid Leukemia

AbbottPhase 2Dormant
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

72 Active assets in the Chronic Lymphoid Leukemia cohort.

Asset / SponsorPhaseRating
Humax-Cd20
Emory University
Phase 4BBB
Acalabrutinib
Zulfa Omer
Phase 4BBB
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Zulfa Omer
Phase 4BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Abt-263 is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
62 / 100
View asset →
lymphoid neoplasmDormant
B
Indicative ·
60 / 100
View asset →
non-Hodgkin lymphomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →